United States Food and Drug Administration (FDA): September 28, 2013 “The Skeptics™” Burzynski discussion: By Bob Blaskiewicz – 2:19:51

20131021-200529.jpg

20131021-200553.jpg
[1] – September 28, 2013 “The Skeptics™” Burzynski discussion: By Bob Blaskiewicz – 2:19:51
======================================
BB – Bob Blaskiewicz
——————————————————————
DJT – Didymus Judas Thomas
======================================
0:47:00
——————————————————————
BB“Ummm, o-kay”

“Uh, I want to turn this over to the people who are watching”

“Um, I want to give them a a chance to address you as well”

“Uhmmm, hi everyone”
——————————————————————
0:48:00
——————————————————————
0:53:00
——————————————————————
BB“A every time that I and and and and, and David (James @StortSkeptic the Skeptic Canary) points this out, that um, you you know you’re not going to speculate about the the FDA but then at every turn you’re invoking the FDA as being obstructionist
——————————————————————
0:54:02
——————————————————————
BB“I, I just find that to be contradictory and and self-defeating
======================================
DJT – Bob, exactly where did I invoke “the FDA as being obstructionist” ?
======================================
1:02:00
——————————————————————
BB“Um, it’s it’s it’s not the FDA’s, but you understand it’s not the FDA’s job to tell someone that their drug doesn’t work
——————————————————————
1:03:00
——————————————————————
BB“it’s it’s it’s up to Burzynski

“It’s up to Burzynski to show that his drug does work”

“And it’s always been his burden of proof

“He’s the one that’s been claiming this miracle cancer cure, forever”
======================================
DJT – Bob, Burzynski showed and proved what he needed to prove to the FDA in order to do phase 2 clinical trials, 9/3/2004 – FDA granted “orphan drug designation” (“ODD”) for Antineoplastons (A10 & AS2-1 Antineoplaston) for treatment of patients with brain stem glioma, .10/30/2008 – FDA granted “orphan drug designation” (“ODD”) for Antineoplastons (A10 and AS2-1 Antineoplaston) for treatment of gliomas, and FDA approved phase 3 [1-2]

Oh, and Bob, exactly when did Burzynski 1st claim “this miracle cancer cure” ?
======================================
1:04:02
——————————————————————
BB“Um, that we’d love to see, however we can’t see, however we can’t see it because of proti protri proprietary uh protections that the FDA is giving to Burzynski, right ?”

They’re not sharing his trial designs because they are his trial designs, right ?”

“That the makeup of his drug that he’s distributing are his, uh design, and his intellectual property

“So the FDA is protecting him, uh from outside scrutiny
======================================
DJT – Bob, you make it sound like it’s part of some grand “conspiracy” between Burzynski and the FDA to keep information from “The Skeptics™” [3]
——————————————————————
21CFR601

Subpart F–Confidentiality of Information

Sec. 601.50

Confidentiality of data and information in an investigational new drug notice for a biological product

(a) The existence of an IND notice for a biological product will not be disclosed by the Food and Drug Administration unless it has previously been publicly disclosed or acknowledged
======================================
BB“While you may imagine that that, that that the FDA is is somehow antagonistic toward him

“They’ve given him every opportunity, over 60 opportunities to prove himself worth uh their confidence and hasn’t
======================================
DJT – Bob, that certainly explains the 9/3/2004 and .10/30/2008 ODD’s and phase 3 clinical trial approvals by the FDA – NOT [1-2]
======================================
1:05:00
——————————————————————
1:42:00
——————————————————————
BB“I don’t, the thing is though that, that that’s a inver, shifting the burden of proof off of Burzynski”

“Burzynski has to prove them wrong, has to prove him right”

“The FDA is not there to say this doesn’t work”
======================================
DJT – Bob, who initiated and put into place the clinical trial hold ?

Burzynski ?

FDA ?

Both ?
======================================
1:43:30
——————————————————————
BB“So, I mean, honestly, um, saying “Well, when the F, FDA tells you that it doesn’t work, the FDA’s never gonna say that because that’s not their job
——————————————————————
1:44:00
——————————————————————
BB“That’s not an option, because they’re never gonna do it

“They relinquish, a lot of authority, over to Burzynski, and his Institutional Review Board, which, I would mention, has failed 3 reviews in a row”
======================================
Bob, where are the “final reports” for those “3 reviews” ?
======================================
BB“Right ?”

“It is Burzynski’s job to be convincing”

“It is not our uh, uh, it it it he hasn’t produced in decades

“In decades”

“In hundreds and hundreds of patients, who’ve payed to be on this”

“Hell, we’d we’d we’d like a prelim, well when you’re talking about something that is so difficult as brainstem glioma, that type of thing gets, really does in the publishing stream get fast-tracked there”
======================================
DJT – Bob, Burzynski has provided numerous phase 2 clinical trial preliminary reports, which our #fave oncologist has chosen to ignore [4]
======================================
BB“they test it”

“Yeah, and they they they want uh, that was evidence of fast-tracking is what, that rejection was uh e was very quickly
======================================
DJT – Bob, have you checked The Lancet Oncology [5] to see what was so much more important than Burzynski’s “phase 2 clinical trial Progression-Free Survival (PFS) and Overall Survival (OS) re patients 8 – 16 years after diagnosis, results” [6] and the Japanese antineoplaston study ? [7]
======================================
BB“So, how long will it be before Burzynski doesn’t publish, that you decide that uh perhaps he’s he‘s, doesn’t have the goods ?

“Um, so, uh, uh again, the FDA is not the arbiter of this

“It’s ultimately Burzynski”

“You’ve been speculating about what the FDA’s motivation are like crazy”

“Why not speculate about Burzynski a little bit”
======================================
DJT – Well, how have I been speculating ?
======================================
1:46:00
——————————————————————
BB“Well actually I’m not even asking you to speculate about Burzynski, I’m only asking you to tell me, how long would it take, uh how, for him to go unpublished like this, um, for this long, before you would doubt it ?”
======================================
DJT – Note how, above, without proving it, Bob claimed “at every turn you’re invoking the FDA as being obstructionist”, and now, directly above, again, without proving it, Bob claims “You’ve been speculating about what the FDA’s motivation are like crazy”
——————————————————————
DJT – what the journals keep saying, in response
======================================
BB“What ?”
======================================
DJT – You know, are they going to give The Lancet response, like they did in 2 hours and such, saying, “Well, we think your message would be best heard elsewhere,” or they gonna gonna give The Lancet response of, “Well, we don’t have room in our publication this time, well, because we’re full up, so, try and pick another place” ?
======================================
BB“But these but but but that doesn’t have any bearing on

“That doesn’t”

“Oh I’m not asking you how long, how long, would it take you for you to start doubting whether or not he has the goods ?

“How long would it take ?”

“It’s a it’s a it’s a question that should be answered by a number uh uh months ?

“Years ?”

“How long ?”

“It’s been 15 years already”
======================================
DJT – Well, you like to jump up and down with the “15 year” quote, but then again I always get back to, Hey, it’s when, when the report, when the clinical trial is done
——————————————————————
1:47:06
——————————————————————
DJT – Not that he’s been practicing medicine medicine for 36 years, or whatever, it’s when the clin, clinical trial was done
======================================
BB – “I could push it back to 36 years”

“He hasn’t shown that it works for 36 years”

“I can do that”

“I was being nice”
======================================
DJT – Note how Bob acts like he’s been hit with “The Stupid Stick”

If he wants to go back “36 years”, I can refer back to 1991 (11/15/1991) – Michael J. Hawkins, M.D., Chief, Investigational Drug Branch, Department of Health &Human Services (HHS), Public Health Service, National Institutes of Health (NIH), National Cancer Institute (NCI), sent a 1 page Memorandum Re:
Antineoplaston
to Decision Network, which advised, in part:

It was the opinion of the site visit team that antitumor activity was documented in this best case series and that the conduct of Phase II trials was indicated to determine the response rate” [8]
——————————————————————
DJT – The FDA A believes there is evidence of efficacy
======================================
BB – “Perhaps based on bad phase 2”
======================================
DJT – Well, we don’t know that

We don’t have the Freedom of Information Act information
——————————————————————
DJT – Remember, Bob is the one who told me during the 9/28/2013 Google+ Burzynski Discussion Hangout:

“You’re you’re you’re assuming”

“You’re you’re you’re assuming that”

“You’re assuming that”

“Um, I’m not assuming that”

“There is a correct answer here”

“You don’t know”

“You don’t know”

“You need to look into it”

“Alright ?”

“Before you dismiss it you have to look into it”

“Everytime somebody throws uh uh something to me,
I have to look into it”

“That’s just, it’s my responsibility as a reader”

“T t and what I would honestly expect and hope, is that you would be honest about this, to yourself, and and and that’s the thing we don’t, we often don’t realize that we’re not being honest with ourself

“I try to fight against it, constantly”

Bob just ASSUMED that the FDA approved phase 3 clinical trials for Burzynski “Perhaps based on bad phase 2”, but tells me NOT to ASSUME ?
======================================
BB“He withdrew”

“He withdrew the the phase 3 clinical trial”

“I that before recruiting,
although I’ve seen lots of people say they were on a phase 3 clinical trial

“I wonder how that happened”
======================================
DJT – Well, we know what happened in the movie because Eric particularly covered that when they tried to get what, what, was it 200 or 300 something institutions to take on a phase 3, and they refused
======================================
1:48:01
——————————————————————
BB“Uh did do do you think that if they thought that he was a real doctor that they all would have refused like that ?
======================================
DJT – Well, Eric gave the reasons that they said they would not take a particular uh phase 3

And so using that excuse that you you just gave there, I’m not even gonna buy that one, because that’s not one of the reasons
——————————————————————
Note how Bob pulls out the old “if they thought that he was a real doctor” line ?

Is Bob now claiming that Burzynski is NOT even a “real doctor” ?
======================================
BB – “He’s changed things”
======================================
DJT – Eric said they gave
======================================
BB“That The Lancet is a top-tier journal like New England Journal of Medicine

“It’s basically be, besieged by uh 100′s of people submitting their, their, their reports”

“Um, it’s just, you know, let’s say he, someone has such a thin publishing record as Burzynski does, do you think that it’s likely that he will ever get in a top-tier journal ?

“What about the the Public Library of Science?”

“It’s not the only journal there”

“What about BMC Cancer ?”

“There’s lots of places that he can go”
======================================
DJT – We’ll I’m
======================================
BB“Um, and he doesn’t seem to to have evailed himself of that, as far as I can tell

“And I would know because he’d get rejected, or he’d be crowing, you know”
——————————————————————
1:49:02
——————————————————————
BB – “Either way, he’s gonna tell us what happens”

He told us what happened with The Lancet, you know”

“I don’t have any evidence that suggests to me that he’s even trying”
======================================
Note how Bob refers to Burzynski’s numerous publications as “such a thin publishing record”

Bob, do I need to count all of these for you ? [9]
——————————————————————
DJT – Well, I’m, I’m sure that they’re going to keep you appraised just like they have in the past, just like Eric has done in the past

So

I mean, we’ll see what happens with the Japanese study [7]
======================================
BB – “So let’s go back to this”

“How long will it take ?”

“How long will it take before you, the Japanese study’s interesting too because we should be able to find that in the Japanese science databases, and we can find, we can’t find it at all

“We can’t find it anywhere”

“And, and those are in English, so it’s not a language problem

“We can’t find that anywhere”

“We’ve asked”

“We asked Rick Schiff, for, for that study”

“And, and it hasn’t come to us

“He is now I believe on the Board of Directors, over there”
——————————————————————
1:50:00
——————————————————————
BB – “He should have access to this”

“We can’t get it”
======================================
Bob, did you ask:

1. Annals of Oncology 2010;21:viii221 ?

2. European Society for Medical Oncology (ESMO), Colorectal cancer, Abstract: 3558, May 17, 2010 ?

3. Colorectal Cancer Association of Canada, COLORECTAL CANCER RESEARCH, Month Ending June 19, 2009
11. Antineoplaston Therapy Doubles 5-Year Survival Rate Following Curative Resection of Hepatic Mets (May 27/09) pg. 5 of 20 ?

4. Kurume University School of Medicine (Japan) Department of Surgery ?

5. Hideaki Tsuda ? [7]
======================================
BB – “How how long will it take before you recognize that, nothing is forthcoming ?”

“How long would that take ?”
======================================
DJT – Well that’s like me asking “How long is it going to take for y’all’s, y’all‘s Skeptics to respond to my questions ?”

Because y’all haven’t been forthcoming
======================================
BB“Well, I mean, were talking about a blog here

“We’re talking about life”

“No, we’re talking about a blogger’s feelings in that case

“In in this case we’re talking about, 1,000′s of patients, over the course of of of generations, you know”

“This is important stuff”

“This is not eh eh equating what’s happening to to patients with what’s happening to you is is completely off-kilter as far as I can tell

“It’s nothing”

“It’s nothing like you not getting to say something on my web-site”

“You know”

“This is they they have thrown in with Burzynski, and they’ve trusted him, and he’s produced nothing

“Nothing of substance”
——————————————————————
1:51:00
——————————————————————
BB – “Nothing that that has made all of that um, uh, n nothing th th th that uh his peers would take seriously”

“The other thing that that that strikes me now is that, you know, you you you you keep saying that, well Eric is going to to share things with you”

“Does it ever concern you eh uh eh occur to you that Eric might not be reliable ?”
======================================
Bob, do you want to have a contest to determine which of you is more “reliable” ?
======================================
DJT – Well, he gave you The Lancet information and he posted the e-mail in the movie, and Josephine Jones posted a copy of it [6]
======================================
BB“He then, and then he”

“And then he he, you know, the the the the dialogue that sprung up around that was, well see, he’s never going to get to get published”

“Well you’re just setting yourself up for wish fulfillment”

“You want him to be, persecuted, so you are ecstatic when he doesn’t get to publish, which is unfortunate for all the cancer patients, who really thought that one day, all the studies were going to be published”
——————————————————————
1:52:00
======================================
DJT – Well, y’all are free to, you know, claim that all you want, because I don’t always agree with Eric, and uh, he’s free to express his opinion
======================================
BB – “Where has Eric been wrong ?”
======================================
DJT – Well I don’t necessarily believe, what Eric would say about, you know, The Lancet that refused to publish the 2nd one, for the reasons he stated, and which y’all have commented on, including Gorski

You know, I don’t necessarily agree with that

I am more agreeable to y’all, saying that, you know, they’re busy, they’ve got other things to do, but I’m kind of still laughing at their 1st response which he showed in the movie about how they felt about, you know his results would be better in some other publication

I thought that was kind of a ridiculous response to give someone
======================================
BB“It’s it’s it’s it’s a form letter

“You know”

“They’re just saying, “No thanks””

““Thanks, but no thanks” is what they were saying, in the most generic way possible”

“Like I said, they’re besieged by researchers trying to publish
——————————————————————
1:53:05
======================================
DJT – Well you would think that if its a form letter they would use the same form that they used the 2nd time

You know, they didn’t use the same wording that they used the 1st time

I would have think that, you know, their 2nd comment
======================================
BB“So, so, possibly”

“So possibly what you are saying is that they in fact have read it, and after having read it they’ve rejected it”

“Is that what you’re saying ?”

“Because that’s what peer-review is”
======================================
DJT – Nah, I’m not saying that they did that all

I’m just sayin’, you know, that they gave, 2 different responses, and I would think that the 2nd one they gave
======================================
BB – “Do you know it was the same editor, that it came from the same desk ?”

“You can’t make that assumption that that the form letter will be the same form letter every time”

“I mean you just can’t

“I mean in in some ways we have a lot of non-information that you’re filling in, with what you expect, as as opposed to what’s actually really there, and I I I just think you’re putting too much uh stock in one uh, uh, in in in in this uh the publication kerfuffle
——————————————————————
1:54:16
——————————————————————
BB“Um”
======================================
DJT – Well I find it funny, something along the lines of, you know, “We believe your message would be received better elsewhere, you know

I don’t see that as a normal response, a scientific publication would send to someone trying to publish something

I mean, to me that sounds, like, if you’re doing that, and you’re The Lancet Oncology, maybe you need to set some different procedures in place, ‘cuz you would think that with such a great scientific peer-reviewed magazine, that they would have structured things in as far as how they do their operations
======================================
BB“Well, not necessarily

“I’ve been in any # of professional groups where the organization is just not optimal, and publications certainly th there are all sorts of pressures from all sorts of different places”
——————————————————————
1:55:08
——————————————————————
BB“I I have no problems whatsoever with seeing that this might not be completely uh um uh streamlining uniform processes as possible

“The fact that it’s not uniform, doesn’t have anything to do with Burzynski not publishing, not producing good data”

“Not just going to a, you know, god, even if, even if, let’s put it this way, even if he went to a pay to play type publication where you have to pay in order to get your manuscript accepted; and he has the money to do this, it wouldn’t take that much, and he were to put out a good protocol, and he were to show us his data, and he would make his, his his stuff accessible to us, then we could validate it, then we could look at it and say, “Yeah, this is good,” or “No, this is the problem, you have to go back and you have to fix this””

“Right ?”

“So we really, every time we talk about the letter that he got, yeah that doesn’t have much to do with anything, really”
——————————————————————
1:56:02
——————————————————————
BB – “We wanna see the frickin’ data”

“And if he had a cure for some cancers that otherwise don’t have reliable treatments, he has an obligation to get that out there anyway he can

“And if if peer-review doesn’t, you know, play a, if peer-review can’t do it, you know, isn’t fast enough for him, then he should take it to the web, and he should send copies out to every pediatric, uh, you know, oncologist that there is

“That’s the way to do it”
======================================
DJT – Well, I’m sure, I’m sure Gorski would have a comment about that, as he’s commented previously about how he thinks uh Burzynskishould publish
======================================
1:57:10
——————————————————————
BB“It’s the, it’s the data itself

“If if Burzynski is is, is confident in his data, he will put it out there

“Right ?”

“One way or the other”
======================================
DJT – Like I said before

Like I said before on my blog, you know, even if Burzynski publishes his phase 2 information, Gorski can just jump up and down and say, “Well, that just shows evidence of efficacy, you know, it’s not phase 3,
so it doesn’t really prove it”

——————————————————————
1:58:04
——————————————————————
DJT – So then he can go on, you know, for however many years he wants to
======================================
2:01:00
——————————————————————
BB“Um, almost no treatment goes out without trials

“Massive amounts of data are required”
======================================
Bob, do you think that’s the 2.5 million pages of clinical trial data that Fabio said Burzynski sent to the FDA ? [10]
======================================
2:02:00
——————————————————————
BB“Uh, in in in that sense, you know, uh all the the the, you know, kind of back-peddling and and and trying to defend him is is going to, not going to help his case at all
======================================
Bob, exactly where did I exhibit any “kind of back-peddling” ?
======================================
2:03:03
——————————————————————
BB
“You are, honestly as far as I can tell you are doing the um, you know, you’re you’re ah throwing up uh, uh, uh, you’re giving me another uh invisible dragon in the garage, um”
======================================
DJT – Well y’all, y’all can call things what y’all want

I mean, y’all can give these, fallacy arguments and all that garbage that y’all like, because that’s what y’all like to talk about instead of dealing with the issues

I mean, Gorski doesn’t want to deal with the issues
======================================
2:04:11
——————————————————————
BB“Okay, so”

“What you’re telling me is that you trust the FDA to to be able to tell you when he’s not doing, good science, but also that you don’t trust the FDA”

“Do you see an inherent conflict there ?”
======================================
DJT – How did I say I, I didn’t trust them ?
======================================
BB“Well, when I, whenever I would ask about, like, why would these trials aren’t happening uh and, you know, you say well the the FDA’s arranged it

“The FDA’s in control”

“They sign off on these things”

“But they’re they’re they’re they’re at the same that they’re, they’re trustworthy they’re also not trustworthy depending on what you need for the particular argument at the time
——————————————————————
2:05:12
——————————————————————
BB – “You’re suggesting that they’re untrustworthy”
======================================
DJT – No, I’m just sayin’ that I’ve raised questions and none of The Skeptics wanna to uh talk about ‘em [11]
======================================
BB“Do you know that the FDA pulled out of the prosecution ?”

“Did you know that the FDA pulled out of the prosecution um of his criminal case, because they were backing a researcher ?”
======================================
Bob, would that “researcher” be Dvorit D. Samid, who was in Burzynski: Cancer is Serious Business (Part I) ?
——————————————————————
DJT – Well, we know a lot stuff they did, but that still doesn’t impress me that they pulled out of the prosecution

I mean
======================================
BB“Yeah, the the the it wasn’t the FDA who was pressing charges, it was a Federal prosecutor
======================================
DJT – Right
======================================
BB“Right”

“And and, they declined to provide information that the prosecution needed

“That’s important”

“That that that’s really important

“That he has been given the benefit of the doubt, and he has come up wanting, for decades now”
======================================
DJT – Well I find it interesting a lot of this uh, a lot of these letters that were provided between, you know, the government and Burzynski, when the uh phase 2 study was going on, at the behest of the NCI

You know, anybody who reads that stuff knows, that when you just ignore the person that’s been doing, do treating their patients for 20 something years, or close to 20 years, and you change the protocol without his approval, and you don’t use the drugs in the manner that he knows works
======================================
2:10:15
——————————————————————
BB“One of the interesting things about Doubting Thomas that I think you should definitely consider for yourself, is that at some point, when faced with the real opportunity to prove or disprove his assertions, he doubted himself”

“And that’s important”

“And that’s where you’re falling short in the analogy”
======================================
DJT – Well, I think The Skeptics, Skeptics are falling short because, you know, they don’t own up to
======================================
BB – “I’ve laid out exactly what it would take for me to turn on a fucking dime”

“I have, I have made it abundantly clear what I need

“Gorski has made it abundantly clear”

“Everybody else, Guy, and David, and Josephine Jones, uh, the Morgans, all of them have made it abundantly clear, what it would take to change our minds, and you’ve never done that”
——————————————————————
2:11:02
——————————————————————
BB“And even in this, this was an opportunity to do that

“To come up with a basis for understanding, where it’s like, you know what, If we can show this, you know, if we can show a this guy, that, that, there, that his standards are not being met, then, you know, we could possibly have some sort of ongoing dialogue after this”
======================================
DJT – So I can say that since the Mayo Clinic (Correction: M.D. Anderson) finished their study in 2006, and it took them until 2013, to actually publish it, then I can say, well, Burzynski finished his in 2009, which was 3 years later, which would give Burzynski until 2016
======================================
BB“Why wasn’t that study”
======================================
DJT – for me to make up my mind (laughing)
======================================
BB“Why wasn’t that, that that that, still . . again, it it doesn’t seem really to to approach the the the, main question here

“You know, um . . what are the standards that you have that it isn’t, what are your standards to show that it isn’t efficacious ?
——————————————————————
2:12:05
======================================
DJT – Well I can say, well I’m going to have to wait, the same amount of time I had to wait for Mayo (Correction: M.D. Anderson) to publish their study; which was from 2006 to 2013
======================================
BB“Why was the Mayo”

“Why was the Mayo (Correction: M.D. Anderson) study delayed ?”
======================================
Note how Bob ASSUMES that the publishing of the final results of the M.D. Anderson study were delayed
——————————————————————
DJT – How do you know it was delayed ?
======================================
BB“Well you said you had so many years before you finish it and go in”
======================================
DJT – I mean, has anybody
======================================
BB“Why, why did it take so long ?
======================================
DJT – done a review of when a clinical trial is studied, and completed, and how long it took the people to publish it ?

You know

If they could point to me a study that’s done that, and say, well here’s the high end, here’s the low end of the spectrum, here’s the middle
======================================
BB“I have something for you, okay ?”

“Send me that”

“Could you send me that study the way that it was published because um, just just send me the final study, um, to my e-mail address”
======================================
DJT – Sure
======================================
BB“Um, because, I can ask that question of those researchers, why was this study in this time, and what happened in-between”
——————————————————————
2:13:03
——————————————————————
BB – “Why did it take so long for it, for it to come out”
======================================
DJT – Sure, but that’s not gonna, you know like, answer an overall question of, you know, somebody did a comparative study of all clinical trials, and, when they were finished, and at, and when the study was actually published afterwards

You know, that’s only gonna be one, particular clinical study
======================================
BB“Right”

“Um, but it it would, perhaps, answer the question; because you’re using it as an example on the basis of which to dismiss criticism, whether or not, uh, it is the standard, and therefor you’re allowed to accept that Burzynski hasn’t published until 2016, or, um, it’s an anomaly, which is also a possibility, that most stuff comes out more quickly
======================================
DJT – Well, we know that the Declaration of Helsinki doesn’t even give a standard saying, You must publish within x amount of years,” you know ?

So, I’ve yet to find a Skeptic who posted something that said, “Here are the standards, published here”
======================================
2:14:07
——————————————————————
BB“I I, yeah, the other thing that David James points out is you know, why 2016 when he’s had 36 years already ?
======================================
DJT – Again, we get back to, when the clinical trial is finished, not when Burzynski started
======================================
BB“Treating people”
======================================
DJT – I mean, you would expect to find a results to be published after, the final results are in
======================================
BB – “You would expect the Burzynski Patient Group to be a lot bigger after 36 years, and in fact is
======================================
DJT – You would expect some people would want to have confidentiality, and maybe not want to be included
======================================
BB – “So, if you’re unsure about this stuff, if you’re unsure about the the time to publication, why are you defending it so hard, other than saying, “I don’t know, I really need to”
======================================
DJT – Why am I unsure ?
======================================
BB“Uh about the
======================================
DJT – (laughing) I just gave you an example
======================================
BB“The reasons, the reasons for which that he’s, no, why are you defending him so hard, when you’re unsure ?
——————————————————————
2:15:02
======================================
DJT – Oh, who said I was unsure ?

I just gave you an example
——————————————————————
Note how Bob ASSUMES that I’m “unsure” when I had the same answer since 0:32:07 [12]

Bob, who approves “Accelerated Approval” ?

1. FDA ?

2. A peer-reviewed scientific journal ?

3. The Skeptics™ ?

Bob, It’s your unlucky [13]
======================================
REFERENCES:
======================================
[1] – September 28, 2013 “The Skeptics™” Burzynski discussion: By Bob Blaskiewicz – 2:19:51
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/10/04/september-28-2013-the-skeptics-burzynski-discussion-by-bob-blaskiewicz-21951/
======================================
[2] – FDA grants Orphan Drug Designation (ODD) for A10 and AS2-1:
——————————————————————
http://www.burzynskiresearch.com/assets/PressRelease_12022008_BZYR(2).pdf
——————————————————————
josephinejones (@_JosephineJones), D Nile ist http://josephinejones.wordpress.com/2013/01/23/happy-birthday-dr-burzynski-and-goodbye-antineoplastons/comment-page-1/#comment-8921
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/23/josephinejones-_josephinejones-d-nile-ist-httpjosephinejones-wordpress-com20130123happy-birthday-dr-burzynski-and-goodbye-antineoplastonscomment-page-1comment-8921/
======================================
[3] – The Skeptics @Majikthyse reveals madjik research skilz:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/26/the-skeptics-majikthyse-reveals-madjik-research-skilz/
======================================
[4] – Critiquing David H. Gorski, MD, PhD, FACS http://www.sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/21/critiquing-david-h-gorski-md-phd-facs-www-sciencebasedmedicine-orgeditorial-staffdavid-h-gorski-md-phd-managing-editor/
======================================
[5] – The Lancet Oncology
——————————————————————
http://www.thelancet.com/journals/lanonc/onlinefirst
——————————————————————
http://www.thelancet.com/journals/lanonc/issue/current
======================================
[6] – FINALLY, one of “The Skeptics™” has the “Balls” to do what even Dr. David H. “Orac” Gorski would NOT do:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/12/finally-one-of-the-skeptics-has-the-balls-to-do-what-even-dr-david-h-orac-gorski-would-not-do/
======================================
[7] – Burzynski – The Antineoplaston Randomized Japan Phase II Clinical Trial Study:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/28/burzynski-the-antineoplaston-randomized-japan-phase-ii-clinical-trial-study/
======================================
[8] – Critiquing: National Cancer Institute (NCI) at the National Institutes of Health (NIH) CancerNet “fact sheet”:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/19/critiquing-national-cancer-institute-nci-at-the-national-institutes-of-health-nih-cancernet/
======================================
[9] – Stanislaw Rajmund Burzynski Publications:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/16/stanislaw-rajmund-burzynski-publications/
======================================
[10] – Critiquing: In which the latest movie about Stanislaw Burzynski “cancer cure” is reviewed…with Insolence:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/18/critiquing-in-which-the-latest-movie-about-stanislaw-burzynski-cancer-cure-is-reviewed-with-insolence-2/
======================================
[11] – QUESTIONS the Critics and Cynics, “The Skeptics™” do NOT want to ANSWER:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/23/questions-the-critics-and-cynics-the-skeptics-do-not-want-to-answer/
======================================
[12] – The Biggest Loser: “The Skeptics™” Guy Chapman (guychapman @vGuyUK @SceptiGuy) http://www.chapmancentral.co.uk/blahg/ – September 28, 2013 “The Skeptics™” Burzynski discussion: By Bob Blaskiewicz – 2:19:51
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/10/18/the-biggest-loser-the-skeptics-guy-chapman-guychapman-vguyuk-sceptiguy-httpwww-chapmancentral-co-ukblahg-september-28-2013-the-skeptics/
======================================
[13] – Burzynski: Why has the FDA NOT granted Accelerated Approval for Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal) ?:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/28/burzynski-why-has-the-fda-not-granted-accelerated-approval-for-antineoplastons-a10-astengenal-and-as2-1-astugenal/
======================================

Burzynski, Hideaki Tsuda (Japan), and the p53 gene

The p53 gene (Phosphoprotein, protein 53, TP53, Tumor protein 53) was supposedly “discovered in 1979, though I did find references to p53 from 1975:

Experiences with the unprepared homologous vein in the reconstruction of diseased and injured arteries

G Schulze-Bergmann and C Fernandez
Thorac Cardiovasc Surg 23(05):468-471 (1975),

We report that the core protein in the cytoplasm increases the amount of p21 via activating p53, and the core protein in the nucleus decreases the amount of p21 by the p53-independent pathway

and 1977:

Investigation of molecular motion in collagen using the spin-probe technique

T Nagamura and A E Woodward
Biopolymers 16(4):907-919 (1977),

We previously reported that OxLDL activates the tumor suppressor p53 in human fibroblasts [Biochem. Biophys. Res. Commun. 276 (2000) 718]

In the present work, we demonstrate that OxLDL increased intracellular levels of the kinase inhibitor p21waf1 (p21) and of the tumor suppressor Rb

5/1979
http://www.ncbi.nlm.nih.gov/m/pubmed/221923
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse
Proc Natl Acad Sci U S A. 1979 May;76(5):2420-4

p53 web-site:
http://p53.free.fr

It has been called:

“The most famous molecule in cancer research”

p53, a 53-kilodalton protein, was discovered in 1979

Researchers thought it might play a role in cancer

p53 is called:

“the guardian of the genome”

because of its role in conserving stability by preventing genome mutation

Is a tumor suppressor gene

p53, also known as TP53 or tumor protein (EC :2.7.1.37) is a gene that codes for a protein that regulates the cell cycle and hence functions as a tumor suppression

p53 is crucial in multicellular organisms, where it regulates the cell cycle and, thus, functions as a tumor suppressor that is involved in preventing cancer

p53 (also known as protein 53 or tumor protein 53), is a tumor suppressor protein that in humans is encoded by the TP53 gene

In humans, p53 is encoded by the TP53 gene located on the short arm of chromosome 17 (17p13.1)

More than a 1/2 of human cancers expressed a mutant p53 raised extensive clinical possibilities both for diagnosis and treatment

It is mutated in about half of all tumors

The p53 gene is often mutated in lung cancer

One of the most important molecules relating to cancer

Complete information for TP53 gene (protein-coding), tumor protein p53

The tumor suppressor gene p53 is mutated or deleted in over 50% of human tumors

The p53 gene is found in the nucleus of every cell in the human body

the p53 tumor suppressor gene and how it is transformed into a dominant oncogene in human cancer
present at the time of the discovery of p53 in 1979

It was only when the first alterations of the p53 gene in human cancers were discovered 10 years later, in 1989, that p53 started to become really popular, with the title of “molecule of the year”

Hideaki H. Tsuda (Japan) had learned about Burzynski and researched ANP’s independently and published:

1/20/1990 – Tsuda (Japan) – A10

Tsuda also researched the p53 gene and published papers re p53 while continuing ANP research:

p53 research

7/1991 (8/25/2005) – Tsuda H (Japan)
6/1/1992
7/1992 – Tsuda H
9/1992 – Tsuda H
11/1992 (8/25/2005) – Hitoshi Tsuda (Japan)
1993 – Tsuda H
4/1993
10/1993
10/1993
5/15/1994 – Tsuda H
6/1994
8/15/1994 – Tsuda H
12/1/1994 – Tsuda H
12/30/1994 – Tsuda H
3/1995
4/14/1995
6/1995 – Tsuda H
10/31/1995
11/1995 – Tsuda H
3/1996
4/1996
2/1997 – Tsuda H
3/1997 – Tsuda H
6/1997
8/1997
11 – 12/1997
12/1997 – Tsuda H
1998
1/1998
1/1998
3/1998
4/25/1998
7/1998 – Tsuda H
7/29/1998
9 – 10/1998 – Tsuda H
11/1998
3/1999
4/25/1999
5/24/1999 – Tsuda H
1/2000 – Tsuda H
1/2000
4/2000
4/2000 – Tsuda H
2001
5/2001 – Tsuda H
9/2001 – Tsuda H
2002
2002 – Tsuda H
1 – 2/2002
4/2002 – Tsuda H
6/2002
7/2002
2003
1/14/2003 – SRB
12/2003
2004
2/2004
3/2004 – SRB
5/2004 – SRB
9/2004
2005 – SRB
6/2005
8/25/2005 – Tsuda H
12/2005
2/8/2006 – Tsuda H
6/28/2007
7/2007 (6/27/2007)
10/2007
12/1/2007
2009
2009
7/2009 (5/7/2009)
11/2009 (8/6/2009) – Tsuda H
2/2010 – Tsuda H
4/2010 (1/29/2010)
5/2010 (3/5/2010) – Tsuda H
7/2011 (2/11/1011)
12/2011
4/2012 (5/12/2011)
8/2012 – Tsuda H
1/2013
2/6/2013 – Tsuda H

(Publications with “Tsuda” out to the right indicate publications with “p53” in the title, those without “Tsuda” are publications with “p53” in the text, “SRB” indicates Burzynski publications re ANP’s and p53)

The p53 gene like the Rb gene, is a tumor suppressor gene, i.e., its activity stops the formation of tumors
http://www.ncbi.nlm.nih.gov/books/NBK22268

It is now clearly understood that, in cancer, the ras gene can cause a cancer signal to be made (genes that cause cancer are called oncogenes)

It is also known that another gene (p53) normally suppresses tumours (and turns off the cancer process), but somehow fails in cancer patients

Burzynski showed that antineoplastons both turn off the ras gene and restimulate the p53 suppressor

He thinks of antineoplastons as switches turning some things off and others back on

Antineoplastons provide the messages which tell the genes to act

Without enough of these crucial peptides the risk of cancer is higher

Antineoplastons work on at least 100 genes

They ´turn off´ oncogenes which spread cancers; while ´turning on´ tumour surpressor genes which stop cancers growing and spreading

In about 30-40% of all cancers, an oncogene, or cancer gene, known as “ras” is activated

When activated, ras allows a protein to stick to the cell and send an abnormal signal

If we can deactivate ras, we can slow down cancer

Abnormal methylation or mutation of the ras gene causes abnormal activation

Antineoplastons normalize
DNA methylation and deactivate ras oncogene protein, making a gene behave normally

Tumor suppressor genes normally cause proteins to be made that provoke apoptosis — a process that naturally destroys cancer cells

This goes on all the time in healthy tissue

In cancer cells, tumor suppressor genes are shut down; they don’t work

The idea is to reactivate them

The p53 gene is an important tumor suppressor gene

And it is of great interest to us because it’s not working in about 70% of white Americans with brain tumors

In Japanese patients, it doesn’t work in 50 – 60%

One of the antineoplastons reactivates p53

What causes the gene to shut down?

First, abnormal methylation and mutation of the gene itself, and antineoplastons reverse this

Also, three important enzymes relate to how cancer cells multiply

All three involve methylation

We’ve discovered that in normal cells, the enzymes stick together briefly, and then come apart

In cancer cells, they stick together and make the cells keep replicating

It’s as though a switch is stuck in the “on” position

At least three of our antineoplastons make the enzymes disassociate

When the enzymes are normalized, the cancer cells undergo apoptosis, or cell death

This also has to do with normalizing the behavior of cancer cells

“Histone deacetylase inhibitors” are a new class of drugs being tested for cancer

Some of the antineoplastons are natural histone deacetylase inhibitors

Acetylation is a process related to methylation

Both affect how genes behave

One affects the other, so it’s important to address both processes

When cancer cells are treated with drugs that modulate both, you get a better response

We’ve noticed that people who get antineoplastons for cancer treatment receive other benefits as well — for example, they are resistant to common viral infections

Their blood cholesterol is normalized and they are less susceptible to breast cancer and enlargement of the prostate

Their skin is healthier, they are less depressed, and they have more energy

2/6/2013 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/23384409
A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer
BMC Clin Pathol. 2013 Feb 6;13:5. doi: 10.1186/1472-6890-13-5
Department of Basic Pathology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan

1/15/2013 – Tsuda Y (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/23266186
Bioorg Med Chem. 2013 Jan 15;21(2):403-11. doi: 10.1016/j.bmc.2012.11.024. Epub 2012 Nov 29

1/2013 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/23202778
Int J Gynecol Pathol. 2013 Jan;32(1):26-30. doi: 10.1097/PGP.0b013e3182518533

10/2012 (1/13/2012) – Tsuda M (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/22244830
Eur J Cancer. 2012 Oct;48(15):2417-30. doi: 10.1016/j.ejca.2011.12.028. Epub 2012 Jan 13

8/2012 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/22537085
Dose-dependent mesothelioma induction by intraperitoneal administration of multi-wall carbon nanotubes in p53 heterozygous mice
Cancer Sci. 2012 Aug;103(8):1440-4. doi: 10.1111/j.1349-7006.2012.02318.x. Epub 2012 Jun 21
Division of Cellular and Molecular Toxicology, Biological Safety Research Center, National Institute of Health Sciences, Tokyo, Japan

4/2012 (5/12/2011) – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/21562709
Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12

2/2012 –
http://www.ncbi.nlm.nih.gov/m/pubmed/21512767
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes

12/2011 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/21683981
Hum Pathol. 2011 Dec;42(12):1823-32. doi: 10.1016/j.humpath.2011.02.015. Epub 2011 Jun 17

9/14/2011 – Tsuda A (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/21914223
Radiat Oncol. 2011 Sep 14;6:116. doi: 10.1186/1748-717X-6-116

7/2011 (2/11/1011) – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/21315415
Hum Pathol. 2011 Jul;42(7):998-1006. doi: 10.1016/j.humpath.2010.10.020. Epub 2011 Feb 11

5/2010 (3/5/2010) – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/20208478
p53 expression in tumor-stromal fibroblasts forming and not forming fibrotic foci in invasive ductal carcinoma of the breast
Mod Pathol. 2010 May;23(5):662-72. doi: 10.1038/modpathol.2010.47. Epub 2010 Mar 5
Pathology Consultation Service, Clinical Trials and Practice Support Division, Center for Cancer Control and Information Service, National Cancer Center, Chuo-ku, Tokyo, Japan

4/2010 (1/29/2010) – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/20118911
Mod Pathol. 2010 Apr;23(4):581-92. doi: 10.1038/modpathol.2010.3. Epub 2010 Jan 29

2/2010 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/19836055
p53 expression in tumor-stromal fibroblasts is closely associated with the nodal metastasis and outcome of patients with invasive ductal carcinoma who received neoadjuvant therapy
Hum Pathol. 2010 Feb;41(2):262-70. doi: 10.1016/j.humpath.2009.07.021
Clinical Trials and Practice Support Division, Pathology Consultation Service, Center for Cancer Control and Information Services, National Cancer Center, Tokyo 104-0045, Japan. thasebe@ncc.go.jp

11/2009 (8/6/2009) – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/19719774
p53 expression in tumor stromal fibroblasts is associated with the outcome of patients with invasive ductal carcinoma of the breast
Cancer Sci. 2009 Nov;100(11):2101-8. doi: 10.1111/j.1349-7006.2009.01307.x. Epub 2009 Aug 6
Pathology Consultation Service, Clinical Trials and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan. thasebe@ncc.go.jp

9/2009 (2/27/2009) – Tsuda M (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/19298529
J Cell Mol Med. 2009 Sep;13(9B):3251-9. doi: 10.1111/j.1582-4934.2009.00719.x. Epub 2009 Feb 27

7/2009 (5/7/2009) – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/19423649
Carcinogenesis. 2009 Jul;30(7):1139-46. doi: 10.1093/carcin/bgp116. Epub 2009 May 7

2009 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/20104994
Asian Pac J Cancer Prev. 2009;10(5):939-60

2009 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/19472036
Breast Cancer. 2009;16(3):186-201. doi: 10.1007/s12282-009-0124-x. Epub 2009 May 27

12/1/2007 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/18056462
Cancer Res. 2007 Dec 1;67(23):11353-8

10/2007 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/17786323
Int J Oncol. 2007 Oct;31(4):899-906

7/2007 (6/27/2007) – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/17594113
Virchows Arch. 2007 Jul;451(1):27-35. Epub 2007 Jun 27

6/28/2007 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/17682140
Nihon Rinsho. 2007 Jun 28;65 Suppl 6:60-7. Article in Japanese

2/8/2006 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/15876486
Establishment of an apoptosis-sensitive rat mammary carcinoma cell line with a mutation in the DNA-binding region of p53
Cancer Lett. 2006 Feb 8;232(2):279-88
Second Department of Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, Japan

12/2005 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/16311351
J Clin Pathol. 2005 Dec;58(12):1299-304

12/1/2005 – Tsuda M (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/16103879
Oncogene. 2005 Dec 1;24(54):7984-90

8/25/2005 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/1429209
High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy
http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1992.tb02010.x/full

6/2005 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/15958052
Cancer Sci. 2005 Jun;96(6):309-16

2005 – Aging: gene silencing or gene activation?
http://www.ncbi.nlm.nih.gov/m/pubmed/15533642
Med Hypotheses. 2005;64(1):201-8

9/2004 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/15289842
Oncol Rep. 2004 Sep;12(3):587-91

5/2004
http://www.lef.org/magazine/mag2004/may2004_report_mystery_02.htm

(4/2004 – Tsuda T (Japan))
http://www.ncbi.nlm.nih.gov/m/pubmed/15863843
J Dermatol. 2005 Apr;32(4):236-42

3/2004 – The present state of antineoplaston research (1)
http://www.ncbi.nlm.nih.gov/m/pubmed/15035876
Integr Cancer Ther. 2004 Mar;3(1):47-58

2/2004 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/14991533
Hum Pathol. 2004 Feb;35(2):165-75

2004 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/15557791
Oncology. 2004;67(3-4):291-9

12/5/2003 – Tsuda M (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/14607246
Life Sci. 2003 Dec 5;74(2-3):189-97

12/2003 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/14675665
Gynecol Oncol. 2003 Dec;91(3):476-85

4/2003 – Tsuda S (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/12679488
J Clin Endocrinol Metab. 2003 Apr;88(4):1889-96

3/2003 – Tsuda T (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/12619108
The TP53 gene, tobacco exposure, and lung cancer
Hum Mutat. 2003 Mar;21(3):229-39
Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8593, USA

3/2003 (2/24/2003) – Tsuda T (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/12619108
The TP53 gene, tobacco exposure, and lung cancer
Hum Mutat. 2003 Mar;21(3):229-39
Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8593, USA
PDF:
http://p53.free.fr/Database/p53_cancer/Human_Mutation_p53/p53_Lung.pdf
Toshihide Tsuda*
Article first published online: 24 FEB 2003
DOI: 10.1002/humu.10177
http://onlinelibrary.wiley.com/doi/10.1002/humu.10177/abstract

1/14/2003
http://wellnesswillpower.com/wellness/2010/09/17/antineoplastons-and-dr-burzynski
Blog
http://www.killermovies.com/forums/archive/index.php/t-552231-cure-for-cancer.html

http://www.killermovies.com/forums/f11/t552231.html

http://kanker-aktueel.nl/EN/interview-with-dr-burzynski-antineoplastons-from-lef-magazine-about-antineoplastontherapie-and-how-it-works.html

2003 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/12931023
Oncology. 2003;65(2):159-66

7/2002 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/12149146
Jpn J Cancer Res. 2002 Jul;93(7):798-806

6/2002 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/12094701
Nihon Geka Gakkai Zasshi. 2002 Jun;103(6):487-91. Article in Japanese

4/2002 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/12055672
Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer
Hum Pathol. 2002 Apr;33(4):386-91
Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Japan

1 – 2/2002 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/11748457
Oncol Rep. 2002 Jan-Feb;9(1):65-8.

2002 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/12016392
Histological grade, p53, HER2 and hormone receptor status of synchronous bilateral breast carcinoma
Breast Cancer. 2002;9(2):127-33
Department of Surgical Oncology, National Cancer Center Hospital, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan. tfukutom@ncc.go.jp

2002 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/12196721
Breast Cancer. 2002;9(1):43-9

9/2001 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/11567230
Combined analysis of p53 and RB pathways in epithelial ovarian cancer
Hum Pathol. 2001 Sep;32(9):988-96
Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka, Japan

5/2001 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/11344480
Differences in estrogen receptor status, HER2, and p53 comparing metachronous bilateral breast carcinoma
J Surg Oncol. 2001 May;77(1):31-4
Department of Surgical Oncology, National Cancer Center Hospital, Tokyo, Japan

2001 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/11180771
Breast Cancer. 2001;8(1):79-83

4/2000 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/11026026
[p53 as a prognostic factor of breast cancers]
Nihon Rinsho. 2000 Apr;58 Suppl:413-7. Article in Japanese
Pathology Division, National Cancer Center Research Institute

4/2000 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/10849311
Pathol Int. 2000 Apr;50(4):263-72

1/2000 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/10770566
Jpn J Clin Oncol. 2000 Jan;30(1):30-2

1/2000 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/10649273
c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues
J Surg Oncol. 2000 Jan;73(1):17-20
Department of Surgical Oncology, National Cancer Center Hospital, Tokyo, Japan

5/24/1999 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/10395176
Heterozygous p53-deficient mice are not susceptible to 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) carcinogenicity
Cancer Lett. 1999 May 24;139(2):177-82
Experimental Pathology and Chemotherapy Division, National Cancer Center Research Institute, Tokyo, Japan. bpark@gan2.res.ncc.go.jp

4/25/1999 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/11091703
Breast Cancer. 1999 Apr 25;6(2):121-126

3/1999 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/10051471
Hepatology. 1999 Mar;29(3):703-9

11/1998 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/9838905
Gan To Kagaku Ryoho. 1998 Nov;25(13):2043-8. Article in Japanese

9 – 10/1998 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/9732224
The possible prognostic significance of p53 immunostaining status of the primary tumor in patients developing local recurrence after breast-conserving surgery
Oncology. 1998 Sep-Oct;55(5):450-5
Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan

7/29/1998 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/11091655
Breast Cancer. 1998 Jul 25;5(3):251-254

7/1998 – Tsuda S (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/9680114
Significance of chromosomal alterations and mutations of the N-RAS and TP53 genes in relation to leukemogenesis of acute myeloid leukemia
Leuk Res. 1998 Jul;22(7):631-7
Division of Hematology, Kyoto Prefectural Yosanoumi Hospital, Japan

4/25/1998 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/11091649
Breast Cancer. 1998 Apr 25;5(2):201-204

3/1998 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/9541186
Breast Cancer Res Treat. 1998 Mar;48(1):21-32

1/1998 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/9491142
Jpn J Clin Oncol. 1998 Jan;28(1):47-9

1/1998 – Tsuda H (Japan )
http://www.ncbi.nlm.nih.gov/m/pubmed/9491134
Jpn J Clin Oncol. 1998 Jan;28(1):5-11

1998 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/18841336
Breast Cancer. 1998;5(3):251-4. doi: 10.1007/BF02966704

12/1997 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/9437997
Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins
Jpn J Clin Oncol. 1997 Dec;27(6):371-7
Department of Clinical Oncology, National Cancer Center Hospital and Research Institute, Tokyo, Japan

11 – 12/1997 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/9394843
Oncology. 1997 Nov-Dec;54(6):468-74

8/1997 – Tsuda T (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/9262576
Ann Thorac Surg. 1997 Aug;64(2):363-7

6/1997 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/9263537
Jpn J Cancer Res. 1997 Jun;88(6):590-9

3/1997 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/9049201
Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas
Hepatology. 1997 Mar;25(3):575-9
Pathology Division, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan

2/1997 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/9119740
Demonstration of ras and p53 gene mutations in carcinomas in the forestomach and intestine and soft tissue sarcomas induced by N-methyl-N-nitrosourea in the rat
Jpn J Cancer Res. 1997 Feb;88(2):129-36
Second Department of Pathology, Fujita Health University School of Medicine, Toyoake

2/1997 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/9070333
Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer
Jpn J Clin Oncol. 1997 Feb;27(1):6-12
Pathology Division, National Cancer Center Research Institute, Tokyo, Japan

4/1996 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/8641970
Jpn J Cancer Res. 1996 Apr;87(4):385-94

3/1996 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/8702314
Gan To Kagaku Ryoho. 1996 Mar;23 Suppl 1:66-74. Article in Japanese

11/1995 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/8567395
Prognostic value of p53 protein accumulation in cancer cell nuclei in adenocarcinoma of the uterine cervix
Jpn J Cancer Res. 1995 Nov;86(11):1049-53
Pathology Division, National Cancer Center Research Institute and Hospital, Tokyo

10/31/1995 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/11091539
Breast Cancer. 1995 Oct 31;2(2):99-103

6/1995 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/7540234
Natural state of mutant p53 protein and heat shock protein 70 in breast cancer tissues
Lab Invest. 1995 Jun;72(6):707-14
Pathology Division, National Cancer Center Research Institute, Tokyo, Japan

4/14/1995 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/7736451
Cancer Lett. 1995 Apr 14;90(2):157-62

3/1995 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/9815981
Clin Cancer Res. 1995 Mar;1(3):261-7

12/30/1994 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/11091524
Bilateral Breast Cancer in a Patient with a Strong Family History of Cancer: Analysis of p53 Germ Line Mutations
Breast Cancer. 1994 Dec 30;1(2):151-155
Departments of Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, DChuo-ku, Tokyo 104, Japan

12/1/1994 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/7960232
Pathogenetic significance of p53 and c-Ki-ras gene mutations and human papillomavirus DNA integration in adenocarcinoma of the uterine cervix and uterine isthmus
Int J Cancer. 1994 Dec 1;59(5):601-6
Pathology Division, National Cancer Center Research Institute, Tokyo, Japan

8/15/1994 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/8062215
Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression
Cancer Lett. 1994 Aug 15;83(1-2):197-200
http://www.science-direct.com/science/article/pii/0304383594903190

6/1994 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/7913600
Gan To Kagaku Ryoho. 1994 Jun;21 Suppl 2:172-7. Article in Japanese

5/15/1994 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/7910151
Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer
Tsuda H
Int J Cancer. 1994 May 15;57(4):498-503.
Pathology Division, National Cancer Center Research Institute, Tokyo, Japan

10/1993 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/8254955
Rinsho Byori. 1993 Oct;41(10):1081-90. Article in Japanese

10/1993 – Tsuda H ( Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/7902882
Rinsho Byori. 1993 Oct;41(10):1092-8. Article in Japanese

4/1993 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/8099903
Jpn J Cancer Res. 1993 Apr;84(4):394-401
Pathology Division, National Cancer Center Research Institute and Hospital, Tokyo

1993 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/8280380
Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand
(PMID:8280380)
Mol Carcinog. 1993;8(4):312-8
Molecular Carcinogenesis [1993, 8(4):312-318]
http://europepmc.org/abstract/MED/8280380
Pathology Division, National Cancer Center Research Institute, Tokyo, Japan
Type: Journal Article, Research Support, Non-U.S. Gov’t, Comparative Study
DOI: 10.1002/mc.2940080415

11/1992 (8/25/2005) – Hitoshi Tsuda (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/1336492
Frequent Occurrence of p53 Gene Mutations in Uterine Cancers at Advanced Clinical Stage and with Aggressive Histological Phenotype
Jpn J Cancer Res. 1992 Nov;83(11):1184-91
Pathology Division, National Cancer Center Research Institute, Tokyo
http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1992.tb02743.x/full
Article first published online: 25 AUG 2005
DOI: 10.1111/j.1349-7006.1992.tb02743.x

11/1992 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/1330291
p53 gene mutation spectrum in hepatocellular carcinoma
Cancer Res. 1992 Nov 15;52(22):6358-64

9/1992 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/1429209
High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy
Jpn J Cancer Res. 1992 Sep;83(9):978-84

7/1992 – Tsuda H ( Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/1319827
Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma
Cancer Res. 1992 Jul 1;52(13):3674-8

6/1/1992 – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/1591722
Cancer Res. 1992 Jun 1;52(11):3099-102

7/1991 (8/25/2005) – Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/m/pubmed/1679056
Nuclear p53 immunoreaction associated with poor prognosis of breast cancer
Jpn J Cancer Res. 1991 Jul;82(7):835-40
Pathology Division, National Cancer Center Research Institute, Tokyo
http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1991.tb02710.x/full
Article first published online: 25 AUG 2005
DOI: 10.1111/j.1349-7006.1991.tb02710.x
http://ci.nii.ac.jp/naid/80005999302

http://ci.nii.ac.jp/naid/80006541912/en

http://ci.nii.ac.jp/naid/80006541912

http://ci.nii.ac.jp/naid/80006656284

1/21/2013
http://helpwithcancer.org/2013/01/fine-line-between-cancer-therapy-and-cancer-quackery.html
2006 (2012)
http://www.canceractive.com/cancer-active-page-link.aspx?n=1268&Title=Antineoplastons,%20missing%20Peptides%20and%20Burzynski

http://www.canceractive.com/cancer-active-page-link.aspx?n=1268

http://www.canceractive.com/cancer-active-page-link.aspx?n=3081&Title=Antineoplastons

http://www.canceractive.com/cancer-active-page-link.aspx?n=2594
5/2004
http://www.vitaminb17.org/an_interview_with_dr_burzynski.htm
2004 (3/21/2012)
http://kanker-aktueel.nl/EN/interview-with-dr-burzynski-antineoplastons-from-lef-magazine-about-antineoplastontherapie-and-how-it-works.html
6/1995
http://www.karlloren.com/biopsy/p60.htm
1994
http://www.alternative-doctor.com/cancer/mossinterview.htm
1994
http://worldwithoutcancer.org.uk/ralphmoss.html

Burzynski: Japan antineoplaston publications

7/20/1988 – Chemopreventive effect of antineoplaston A-10 on urethane-induced pulmonary neoplasm in mice
http://www.ncbi.nlm.nih.gov/m/pubmed/3183462
Tsuda
N E
Nihon Gan Chiryo Gakkai Shi. 1988 Jul.20; 23 (7):1560-5
23(7):1560-5 (1988)
Nihon Gan Chiryo Gakkai Shi

1/20/1990 – A-10 Injection – The anticancer effect of antineoplaston A-10 on human breast cancer serially transplanted to athymic mice
http://www.ncbi.nlm.nih.gov/m/pubmed/2157780
Nihon Gan Chiryo Gakkai Shi. 1990 Jan 20;25(1):1-5
1990 Tsuda (Japan) et al published with The members of Antineoplaston Study Group
Kurume Med J. 1990;37(2):97-104
http://www.ncbi.nlm.nih.gov/pubmed/2175003
Burzynski References: 1 – 8 and 11 – 14
Abstract:
http://www.jstage.jst.go.jp/article/kurumemedj1954/37/2/37_2_97/_article
References:
http://www.jstage.jst.go.jp/article/kurumemedj1954/37/2/37_2_97/_article/references
PDF
http://www.jstage.jst.go.jp/article/kurumemedj1954/37/2/37_2_97/_pdf
5/1992 Tsuda (Japan) publishes re A-10 Injection:
http://www.ncbi.nlm.nih.gov/m/pubmed/1377669
Burzynski References: 1, 4 – 7 and 9
Nishida (Japan) A-10 Reference: 2
Abstract:
http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1992.tb01960.x/abstract
References:
http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1992.tb01960.x/references
PDF
http://onlinelibrary.wiley.com/store/10.1111/j.1349-7006.1992.tb01960.x/asset/j.1349-7006.1992.tb01960.x.pdf?v=1&t=hdcl29bl&s=dd78f02b92e0f5544c136e7b897a7d65bcf5dc71&systemMessage=Wiley+Online+Library+will+be+disrupted+on+23+February+from+10%3A00-12%3A00+BST+%2805%3A00-07%3A00+EDT%29+for+essential+maintenance
5/1995 Tsuda (Japan) publishes re Antineoplaston:
Kurume Med J. 1995;42(3):133-40
http://www.ncbi.nlm.nih.gov/m/pubmed/7474850
Burzynski References: 1 – 2 and 4
Samid Reference: 7 (who learned from Burzynski re Phenylacetate)
Lee (Japan) A-10 Reference: 3
Nishidi (Japan) A-10 Reference: 6
Abstract:
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/3/42_3_133/_article
References:
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/3/42_3_133/_article/references
PDF
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/3/42_3_133/_pdf
1995 Tsuda (Japan) publishes re A-10 and AS2-1:
Kurume Med J. 1995;42(4):241-9
http://www.ncbi.nlm.nih.gov/m/pubmed/8667595
Burzynski References: 1 – 3 and 5
Nishida et al. (Japan) A-10 Reference: 4 and 7
Muldoon et al. A-10 Reference: 6
Abstract:
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/4/42_4_241/_article
References:
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/4/42_4_241/_article/references
PDF
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/4/42_4_241/_pdf
1996 Tsuda (Japan) publishes re A10 and AS2-1:
Kurume Med J. 1996;43(2):137-47
http://www.ncbi.nlm.nih.gov/m/pubmed/8755117
Burzynski References: 1 – 3, 5 and 7
Samid Reference: 13 (who learned from Burzynski re Phenylacetate)
Nishida et al. (Japan) A10 Reference: 4 and 10
Muldoon et al. A10 Reference: 8
Abstract:
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_article
References:
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_article/references
PDF
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_pdf
7 – 8/2007 (Japan) publishes re A10:
http://www.ncbi.nlm.nih.gov/m/pubmed/17695534
Burzynski References: 1, 3, 5, 13 and 15
Badria (Egypt) A-10 References: 2 and 20
Wang A10 Reference: 4
http://ar.iiarjournals.org/content/27/4B/2427.short
Abstract:
http://ar.iiarjournals.org/content/27/4B/2427.long
PDF
http://ar.iiarjournals.org/content/27/4B/2427.full.pdf
1/2008 (Japan) publishes re antineoplaston:
Breast Cancer. 2008;15(1):73-8. doi: 10.1007/s12282-007-0015-y
Breast Cancer: January 2008, Volume 15, Issue 1, pp 73-78
http://www.ncbi.nlm.nih.gov/m/pubmed/18224398
Burzynski Reference: 12
Tsuda (Japan) Antineoplaston Reference: 13
http://link.springer.com/article/10.1007%2Fs12282-007-0015-y

1990 – Inhibitory effect of antineoplaston A-10 on breast cancer transplanted to athymic mice and human hepatocellular carcinoma cell lines
http://www.ncbi.nlm.nih.gov/m/pubmed/2175003
H TSUDA
Kurume University School of Medicine, Japan
Kurume Med J 37 (2):97-104 (1990)
Kurume Medical Journal
J-STAGE, Japan Science and Technology Information Aggregator, Electronic
http://www.jstage.jst.go.jp/article/kurumemedj1954/37/2/37_2_97/_article

http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1992.tb01960.x/abstract

http://ci.nii.ac.jp/naid/130000888719

1991 – Inhibitory effect of orally administered antineoplaston A10 on the growth curve of human breast cancer transplanted to athymic mice
J Jpn Soc Cancer Ther 26:595-601, 1991

1992 – antineoplaston – Prevention of drug induced DNA hypermethylation by antineoplaston components
LIAU M C
Intl J Exp Clin Chemother 1992; 5:19-27
https://data.epo.org/publication-server/pdf-document?PN=EP0680756%20EP%200680756&iDocId=4830495&iepatch=.pdf

http://eng.med.wanfangdata.com.cn/PaperDetail.aspx?qkid=zgzllc-e&qcode=zgzllc-e200504004

http://so.med.wanfangdata.com.cn/ViewHTML/PeriodicalPaper_zgzllc-e200504004.aspx

5/1992 – The inhibitory effect of the combination of antineoplaston A-10 injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of human hepatocellular carcinoma
http://www.ncbi.nlm.nih.gov/m/pubmed/1377669
The Inhibitory Effect of the Combination of Antineoplaston A-10 Injection with a Small Dose of cis-Diamminedichloroplatinum on Cell and Tumor Growth of Human Hepatocellular Carcinoma
H TSUDA
Department of Anesthesiology, Kurume University, School of Medicine, Fukuoka-ken
Jpn J Cancer Res. 1992 May;83(5):527-31
Jpn. J. Cancer Res. 83, 527-531
Jpn J Cancer Res. 1992 May;83 (5):527-31
Jpn J Cancer Res 83 (5):527-31 (1992)
Article first published online: 26 AUG 2005
DOI: 10.1111/j.1349-7006.1992.tb01960.x
Japan Journal Cancer Research
http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1992.tb01960.x/abstract

http://onlinelibrary.wiley.com/store/10.1111/j.1349-7006.1992.tb01960.x/asset/j.1349-7006.1992.tb01960.x.pdf?v=1&t=hd97ht7z&s=3481466c7830e5f8e2bb925a698de6f8155da747

http://onlinelibrary.wiley.com/store/10.1111/j.1349-7006.1992.tb01960.x/asset/j.1349-7006.1992.tb01960.x.pdf;jsessionid=4ECD3F595A3971B5AB87763862867844.d03t02?v=1&t=hbmd55gj&s=a14b626a37db3ecd558109cee30dfe26c71827763862867844
Cancer Science
Cancer …, Wiley Online Library
2003 – AS2-1 –
Oncology …,
The preventive effect of antineoplaston AS2-1 on HCC recurrence

1995 – (Clinically tested) – The effect of Antineoplaston, a new antitumor agent on malignant brain tumors
http://www.ncbi.nlm.nih.gov/m/pubmed/7474850
H H TSUDA
Department of Neurosurgery, Kurume University School of Medicine, Japan
Kurume Med J. 1995;42(3):133-40
Kurume Med J 42(3):133-40 (1995)
Kurume Medical Journal
J-STAGE, Japan Science and Technology Information Aggregator, Electronic

1995 – Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients
http://www.ncbi.nlm.nih.gov/m/pubmed/8667595
H Tsuda
Kurume Med J 42 (4):241-9 (1995)
Department of Anesthesiology, Kurume University School of Medicine, Japanu
Kurume Med Journal
J-STAGE, Japan Science and Technology Information Aggregator, Electronic
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/4/42_4_241/_article

http://www.jstage.jst.go.jp/article/kurumemedj1954/42/4/42_4_241/_pdf

1996 – Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma
http://www.ncbi.nlm.nih.gov/m/pubmed/8755117
Tsuda H
Department of Anesthesiology, Kurume University School of Medicine, Japan
Kurume Med J 43 (2):137-47 (1996)
J-STAGE, Japan Science and Technology Information Aggregator, Electronic
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_article

http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_pdf

11-12/1997 – phase I clinical trial – Antineoplaston AS2-1 for maintenance therapy in liver cancer
http://www.ncbi.nlm.nih.gov/m/pubmed/21590224
H Tsuda
http://www.ncbi.nlm.nih.gov/m/pubmed/21590224
KURUME UNIV,SCH MED,DEPT SURG,KURUME,FUKUOKA,JAPAN. KURUME UNIV,SCH MED,DEPT INTERNAL MED,KURUME,FUKUOKA,JAPAN. KURUME UNIV,SCH MED,DEPT RADIOL,KURUME,FUKUOKA,JAPAN
4 (6):1213-6
Oncol Rep. 1997 Nov-Dec;4(6):1213-6
Oncol Rep. 1997; 4:1213- 1216
Oncol Rep 4 (6):1213-6 (1997)
Oncology Reports
http://www.spandidos-publications.com/or/4/6/1213

5 – 6/1998 – A10 and AS2-1 – I – Quick response of advanced cancer to chemoradiation therapy with antineoplastons
http://www.ncbi.nlm.nih.gov/m/pubmed/9538158
H Tsuda
http://www.ncbi.nlm.nih.gov/m/pubmed/9538158
Department of Anesthesiology, Kurume University, School of Medicine, Kurumeshi, Fukuokaken, Japan
5 (3):597-600
Oncol. Rep. 1998;5:597–600
Oncol Rep. 1998 May-Jun;5 (3):597-600
Oncol Rep 5 (3):597-600 (1998)
Oncology Reports
http://www.spandidos-publications.com/or/5/3/597

11-12/1998 – A10 I – I – Antineoplaston treatment for advanced hepatocellular carcinoma
http://www.ncbi.nlm.nih.gov/m/pubmed/9769368
H Tsuda
Department of Radiology, Kumabe Hospital, Kurume University School of Medicine, Kurumeshi, Fukuokaken, Japan
5 (6):1363-7
Oncol Rep. 1998;5:1363-1367
Oncol Rep. 1998 Nov-Dec;5 (6):1363-7
Oncol Rep 5 (6):1363-7 (1998)
Oncology Reports, Spandidos Publications
http://www.spandidos-publications.com/or/5/6/1363

2002 – Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma
H TSUDA
Department of Anesthesiology, Kurume University School of Medicine, Japan
43 (2):137-47 PMID 8755117
J-STAGE, Japan Science and Technology Information Aggregator, Electronic
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_article

http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_pdf

2002 – A10 & AS2-1 – A novel strategy for remission induction and maintenance in cancer therapy
http://www.ncbi.nlm.nih.gov/m/pubmed/11748457
H Tsuda
Department of Anesthesiology, Kurume University, School of Medicine, Fukuoka-ken , Japan
mx2.tiki.ne.jp
Oncol Rep 2002;9:65–8
Oncol. Rep. 2002;9:65-68
Oncol Rep 9(1):65-8 (2002)
Oncology Reports, Spandidos Publications
http://www.spandidos-publications.com/or/9/1/65

2002 -The preventive effect of antineoplaston AS2-1 on HCC recurrence
Tsuda
Oncology Reports 2002; 10: 391-397
http://www.burzynskiclinic.com/images/stories/Publications/964.pdf

2003 – Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases: report of a case
http://www.ncbi.nlm.nih.gov/m/pubmed/12768372
TSUDA H
Surg Today 2003
http://www.springerlink.com/content/b48ch3ha165nbrqp

http://sciencelinks.jp/j-east/article/200313/000020031303A0389449.php

http://ci.nii.ac.jp/naid/10015483373

3 – 4/2003 – Phase II Clinical Trial – The preventive effect of antineoplaston AS2-1 on HCC recurrence
http://www.ncbi.nlm.nih.gov/m/pubmed/12579278
Hideaki H TSUDA
Department of Anesthesiology, Kurume Daiichi Social Insurance Hospital, Kushihara Kurumeshi, Fukuoka, Japan
Oncol Rep. 2003 Mar-Apr;10(2):391-7
Oncol Rep 10 (2):391-7 (2003)
Oncol Rep 2003;10:391–7
Oncol Rep. 2003;10:391-397
Oncology Reports
Spandidos Publications
http://www.spandidos-publications.com/or/10/2/391

http://link.springer.com/article/10.1007%2Fs10595-002-2503-2?LI=true

6/2003 – A10 & AS2-1 – Phase II Clinical Trial – Long-Term Survival Following Treatment with Antineoplastons for Colon Cancer with Unresectable Multiple Liver Metastases:
Report of a Case
http://www.ncbi.nlm.nih.gov/m/pubmed/12768372
Hideaki Tsuda
Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan
Surg Today. 2003;33(6):448-53
Surg Today 2003; 33:448–53
Surg Today. 2003; 33:448-453
33 (6):448-53
DOI: 10.1007/s10595-002-2503-2
Surgery Today, Springer

http://link.springer.com/article/10.1007%2Fs10595-002-2503-2

http://link.springer.com/article/10.1007%2Fs10595-002-2503-2?LI=true

http://link.springer.com/content/pdf/10.1007%2Fs10595-002-2503-2

http://sciencelinks.jp/j-east/article/200313/000020031303A0389449.php

http://ci.nii.ac.jp/naid/10015483373

9/2003 – [Anti-proliferative effects of biochemical defense modifier antineoplaston in colorectal carcinoma]
http://www.ncbi.nlm.nih.gov/m/pubmed/14574945
Department of Surgery, Kurume University School of Medicine
61 Suppl 7:505-9
Nihon Rinsho (2003)
Nihon Rinsho. 2003 Sep; 61 Suppl 7:505-9 Article in Japanese

2004 -Analysis of cell growth inhibitory effects of antineoplaston through MAPK in human breast cancer cell line SKBR-3
http://www.ncbi.nlm.nih.gov/m/pubmed/14755017
TSUDA
EJC Supplements 2 (3): 2 (2004),
DOI: 10.1016/S1359-6349(04)90794-X
The Oncologist, AlphaMed Press
Complementary and alternative therapies for cancer
http://m.theoncologist.alphamedpress.org/content/9/1/80.short

http://theoncologist.alphamedpress.org

http://m.theoncologist.alphamedpress.org/content/9/1/80.long

http://m.theoncologist.alphamedpress.org/content/9/1/80.full.pdf

http://theoncologist.alphamedpress.org/content/9/1/80.full?sid=09bf7d6b-2d6c-4097-a48d-ef768e65569b

http://theoncologist.alphamedpress.org/content/9/1/80.full.pdf?sid=30deadf2-7850-4ea2-9760-664ceee77eed

http://www.oncocure.ca/assets/byTopic/IntegrativeOncology/2-CAM%20Therapies%20in%20CA-Oncologist%202004.pdf

http://intl-cme.alphamedpress.org/cgi/hierarchy/ampcme_course;91080

http://cme.alphamedpress.org/cgi/hierarchy/ampcme_course;91080

http://www.integratedhealthclinic.com/assets/byTopic/IntegrativeOncology/2-CAM%20Therapies%20in%20CA-Oncologist%202004.pdf

http://theoncologist.alphamedpress.org/content/9/1/80.full?sid=09bf7d6b-2d6c-4097-a48d-ef768e65569b

http://theoncologist.alphamedpress.org/content/9/1/80.full.pdf?sid=30deadf2-7850-4ea2-9760-664ceee77eed

http://www.oncocure.ca/assets/byTopic/IntegrativeOncology/2-CAM%20Therapies%20in%20CA-Oncologist%202004.pdf

http://intl-cme.alphamedpress.org/cgi/hierarchy/ampcme_course;91080

http://cme.alphamedpress.org/cgi/hierarchy/ampcme_course;91080

http://www.integratedhealthclinic.com/assets/byTopic/IntegrativeOncology/2-CAM%20Therapies%20in%20CA-Oncologist%202004.pdf

2005 – Effects of antineoplaston AS2-1 against post-operative lung metastasis in orthotopically implanted colon cancer in nude rat
http://www.ncbi.nlm.nih.gov/m/pubmed/15706406
Tsuda H
Department of Surgery, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
Oncol Rep. 2005 Mar;13(3):389-95
Oncology …,

3/2005 – Effects of antineoplaston AS2-1 against post-operative lung metastasis in orthotopically implanted colon cancer in nude rat
http://www.ncbi.nlm.nih.gov/m/pubmed/15706406
Hideaki TSUDA
Department of Surgery, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
Oncol Rep 13 (3): 389-95 (2005)
Oncol Rep. 2005 Mar; 13 (3):389-95
Oncology Reports, 3/2005, Volume 13 Number 3
Pages: 389-395 Oncology Reports, Spandidos Publications
http://www.spandidos-publications.com/or/13/3/389

8/2005 – Antineoplaston A10 – Antineoplaston induces G1 arrest by PKCα and MAPK pathway in SKBR-3 breast cancer cells
http://www.ncbi.nlm.nih.gov/m/pubmed/16012735
Antineoplaston induces G1 arrest by PKCo and MAPK pathway in SKBR-3 breast cancer cells
Antineoplaston induces G(1) arrest by PKCalpha and MAPK pathway in SKBR-3 breast cancer cells
Hideaki H TSUDA
Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan
med.kurume-u.ac.jp
Oncol Rep 14(2):489-94 (2005)
Oncol Rep. 8/2005; 14(2):489-94
Oncology Reports, 8/2005, Volume 14 Number 2
Pages: 489-494
Oncol Rep. 2005; 14:489–94
Oncol. Rep. 14, 489–494
Oncology .Reports, Spandidos Publications
http://www.spandidos-publications.com/or/14/2/489

http://gyouseki.kurume-u.ac.jp/PDF/ichiran_2005.pdf

http://research.kurume-u.ac.jp/K90RES.php?scode=49485632873864

http://onlinelibrary.wiley.com/doi/10.1002/iub.574/abstract

http://onlinelibrary.wiley.com/doi/10.1002/iub.574/full

http://onlinelibrary.wiley.com/store/10.1002/iub.574/asset/574_ftp.pdf?v=1&t=hbr9z60q&s=0b1c1e8655db9c54b45dbf72062e8b11cb7895ac

2006 – Inhibitory Effect of Antineoplaston A10 and AS2-1 on Human Hepatocellular Carcinoma
http://www.ncbi.nlm.nih.gov/m/pubmed/8755117
TSUDA
med.kurume-u.ac.jp
Kurume Medical Journal
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_article

http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_pdf

7 – 8/27/2007 – Induction of apoptosis in human hepatocellular carcinoma cells by synthetic antineoplaston A10
http://www.ncbi.nlm.nih.gov/m/pubmed/17695534
Induction of Apoptosis in Human Hepatocellular Carcinoma Cells by Synthetic Antineoplaston A10,
School of Pharmaceutical Sciences, Shandong University, Jinan, Japan
Anticancer Research, Vol. 27, No. 4B, 2007, pp. 2427-2431
Anticancer Res 27(4B):2427-31 (2007)
Anticancer Res. 7 – 8/2007; 27(4B):2427-31
Anticancer Research
International Journal of Cancer Treatment
HighWire Press
http://ar.iiarjournals.org/content/27/4B/2427.short

http://ar.iiarjournals.org/content/27/4B/2427.long

http://ar.iiarjournals.org/content/27/4B/2427.full.pdf

http://www.iiar-anticancer.org/main.php?pid=3398&id=2&ch=52&gch=&volume=27&issue=4B&show=details&page=2

1/2008 – antineoplaston – Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer
http://www.ncbi.nlm.nih.gov/m/pubmed/18224398
15(1):73-8
Department of Surgery, Kurume University, Fukuoka, Japan
Breast Cancer 15(1):73-8 (2008)
DOI: 10.1007/s12282-007-0015-y
http://link.springer.com/article/10.1007%2Fs12282-007-0015-y

http://www.springerlink.com/content/p724x34746l56v73

http://ci.nii.ac.jp/naid/10021288533

2010 – Antineoplastons – Japan – Tsuda – Phase II
Randomized Phase II Study of Hepatic Arterial Infusion with or without Antineoplastons as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer

Annals of Oncology 2010;21:viii221
http://www.burzynskiclinic.com/images/stories/Publications/8774.pdf

Randomized Phase II Study of Hepatic Arterial Infusion with or without Antineoplastons as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer
https://stanislawrajmundburzynski.wordpress.com/2013/03/28/burzynski-the-antineoplaston-randomized-japan-phase-ii-clinical-trial-study
Annals of Oncology 2010;21:viii221
http://www.burzynskiclinic.com/images/stories/Publications/8774.pdf

http://oncologypro.esmo.org/meeting-resources/meeting-abstracts/european-society-for-medical-oncology-esmo-2010/randomized-phase-ii-study-of-hepatic-ar-3558.aspx

http://abstracts.webges.com/viewing/view.php?congress=esmo2010&congress_id=296&publication_id=3558
11. Antineoplaston Therapy Doubles 5-Year Survival Rate Following Curative Resection of Hepatic Mets

(May 27/09)

Positive results were borne from a phase II clinical study of Antineoplaston therapy (ANP therapy) in metastatic colon cancer following curative resection of liver mets

The study was performed in Japan

The study consisted of 65 colon cancer patients who had undergone curative resection of their liver mets and were randomized to one of the following groups:

1. intrahepatic infusion of 5FU

2. intrahepatic infusion of 5FU plus IV ANP therapy given (a) daily for seven days following hepatic
resection, and (b) ANP therapy given orally daily for one year

There was a significant difference in overall survival between the 2 groups, with the 5 year survival rate in the 5FU plus ANP therapy arm being 63% vs. 32% in the 5FU only arm

Recurrence rate also differed for the 2 groups, which were 34% and 69% respectively

Lead investigator claims that ANP therapy may find application not only in the treatment of brain tumors as reported previously, but also in the more common colorectal cancer
http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf
Antineoplaston Therapy Doubles 5-Year Survival Rate Following Curative Resection of Hepatic Mets

Randomized Phase II Study of Hepatic Arterial Infusion with or without Antineoplastons as Adjuvant Therapy after Hepatectomy for Liver Metastases from Colorectal Cancer
http://oncologypro.esmo.org/meeting-resources/meeting-abstracts/european-society-for-medical-oncology-esmo-2010/randomized-phase-ii-study-of-hepatic-ar-3558.aspx
Publication date: May 17, 2010
Category: Colorectal cancer
Publisher: ESMO
Y. Ogata; K. Shirouzu; K. Matono; M. Ushijima; S. Uchida; H. Tsuda
http://abstracts.webges.com/viewing/view.php?congress=esmo2010&congress_id=296&publication_id=3558
Abstract: 3558
Congress: ESMO 2010
Type: Publication
Topic: Colorectal cancer
Authors: Y. Ogata, K. Shirouzu, K. Matono, M. Ushijima, S. Uchida, H. Tsuda; Kurume/JP
http://www.biomeddefine.com/sdx/t31/all/100/epithelial+neoplasm+glandular+piperidines+chemical+ingredient.html

http://www.biomeddefine.com/sdx/t31/all/100/ca+secondary+cancer+piperidines+chemical+ingredient.html
Antineoplaston Therapy Doubles Five-Year Survival Rate Following Curative Resection of Hepatic Mets

Metastatic Colon Cancer:

In a Randomized Phase II Clinical Study, Antineoplaston Therapy Doubled the 5-Year Survival Rate Following Curative Resection of Hepatic Metastases
http://www.drugs.com/clinical_trials/metastatic-colon-cancer-randomized-phase-ii-clinical-study-antineoplaston-therapy-doubled-5-year-7307.html
HOUSTON–(BUSINESS WIRE)–May 27, 2009 – The Burzynski Research Institute, Inc.

(BRI) is pleased to announce the results of a randomized Phase II clinical study of antineoplaston therapy (ANP therapy) in metastatic colon cancer following curative resection of hepatic metastases

The study was performed at the Kurume University School of Medicine (Japan) in the Department of Surgery

A report of the study results is currently in press
http://oncologypro.esmo.org/meeting-resources/meeting-abstracts/european-society-for-medical-oncology-esmo-2010/randomized-phase-ii-study-of-hepatic-ar-3558.aspx

http://abstracts.webges.com/viewing/view.php?congress=esmo2010&congress_id=296&publication_id=3558
11. Antineoplaston Therapy Doubles 5-Year Survival Rate Following Curative Resection of Hepatic Mets (May 27/09)
Positive results were borne from a phase II clinical study of Antineoplaston therapy (ANP therapy) in metastatic colon cancer following curative resection of liver mets
study was performed in Japan
study consisted of 65 colon cancer patients who had undergone curative resection of their liver mets and were randomized to one of the following groups:
1. infusion of x
2. infusion of x plus IV ANP therapy
significant difference in overall survival between the 2 groups
5 year survival rate
63% in x plus ANP therapy arm
32% in the x only arm
Recurrence rate for the 2 groups
34%
69%
http://finance.yahoo.com/news/Metastatic-Colon-Cancer-In-a-bw-15355368.html?.v=1

http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf

http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf
Annals of Oncology 2010;21:viii221

http://oncologypro.esmo.org/meeting-resources/meeting-abstracts/european-society-for-medical-oncology-esmo-2010/randomized-phase-ii-study-of-hepatic-ar-3558.aspx

http://abstracts.webges.com/viewing/view.php?congress=esmo2010&congress_id=296&publication_id=3558

http://www.biomeddefine.com/sdx/t31/all/100/epithelial+neoplasm+glandular+piperidines+chemical+ingredient.html

http://www.biomeddefine.com/sdx/t31/all/100/ca+secondary+cancer+piperidines+chemical+ingredient.html

http://www.drugs.com/clinical_trials/metastatic-colon-cancer-randomized-phase-ii-clinical-study-antineoplaston-therapy-doubled-5-year-7307.html